Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07598448 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableRecruitment openedStart date changed from estimate of Sep 21, 2026 to Sep 22, 2026 · Study sites: 0 to 1Show 2 more changesShow less
Start date changed from estimate of Sep 21, 2026 to Sep 22, 2026
Study sites: 0 to 1
MinorStart date pushed from Sep 10, 2026 to Sep 21, 2026Secondary endpoints: details revised at 4 of 42 entries · Eligibility criteria expanded, about 3 wordsShow 2 more changesShow less
Secondary endpoints: details revised at 4 of 42 entries
Eligibility criteria expanded, about 3 words
MinorStart date: Aug 23, 2026 to Sep 10, 2026v4
MinorRe-verified, no change to tracked fieldsv3
NotableStart date: May 16, 2026 to Aug 23, 2026Primary and study completion pushed from Sep 30, 2026 to Dec 15, 2026v2Show 1 more changeShow less
Primary and study completion pushed from Sep 30, 2026 to Dec 15, 2026
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.